{"pmid":32388390,"title":"The powerful immune system against powerful COVID-19: A hypothesis.","text":["The powerful immune system against powerful COVID-19: A hypothesis.","On March 11, 2020, the World Health Organization declared the coronavirus outbreak a pandemic. Since December 2019, the world has experienced an outbreak of coronavirus disease 2019 (COVID-19). Epidemiology, risk factors, and clinical characteristics of patients with COVID-19 have been reported but the factors affecting the immune system against COVID-19 have not been well described. In this article, we provide a novel hypothesis to describe how an increase in cellular adenosine triphosphate (c-ATP) can potentially improve the efficiency of innate and adaptive immune systems to either prevent or fight off COVID-19.","Med Hypotheses","Taghizadeh-Hesary, Farzad","Akbari, Hassan","32388390"],"abstract":["On March 11, 2020, the World Health Organization declared the coronavirus outbreak a pandemic. Since December 2019, the world has experienced an outbreak of coronavirus disease 2019 (COVID-19). Epidemiology, risk factors, and clinical characteristics of patients with COVID-19 have been reported but the factors affecting the immune system against COVID-19 have not been well described. In this article, we provide a novel hypothesis to describe how an increase in cellular adenosine triphosphate (c-ATP) can potentially improve the efficiency of innate and adaptive immune systems to either prevent or fight off COVID-19."],"journal":"Med Hypotheses","authors":["Taghizadeh-Hesary, Farzad","Akbari, Hassan"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388390","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.mehy.2020.109762","keywords":["atp","covid-19","immune dysfunction"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666428892256141313,"score":9.490897,"similar":[{"pmid":32439309,"title":"[Narrative review of the immune response against coronavirus: An overview, applicability for SARS-COV-2, and therapeutic implications].","text":["[Narrative review of the immune response against coronavirus: An overview, applicability for SARS-COV-2, and therapeutic implications].","The new coronavirus (SARS-CoV-2) that causes a severe acute respiratory syndrome emerges in Wuhan, China, in December 2019. It produces the aforementioned disease due to coronavirus 2019 (COVID-19), and has led to a declaration of a world public health emergency by the World Health Organisation. This new SARS-CoV-2 virus could share characteristics and an immune response similar to those described for other coronavirus. Given its activity on the interferon pathway, and the manner in which it dysregulates innate immunity, the use of treatments directed at modulating or containing this could be of interest. A narrative review was made of the current evidence about immunity against coronavirus and its applicability to SARS-CoV-2. The physiopathogenesis is also described, along with the underlying leucocyte activity, with the intention of clarifying the possible usefulness of inflammatory biomarkers and the development of personalised treatments.","An Pediatr (Barc)","Garcia-Salido, Alberto","32439309"],"abstract":["The new coronavirus (SARS-CoV-2) that causes a severe acute respiratory syndrome emerges in Wuhan, China, in December 2019. It produces the aforementioned disease due to coronavirus 2019 (COVID-19), and has led to a declaration of a world public health emergency by the World Health Organisation. This new SARS-CoV-2 virus could share characteristics and an immune response similar to those described for other coronavirus. Given its activity on the interferon pathway, and the manner in which it dysregulates innate immunity, the use of treatments directed at modulating or containing this could be of interest. A narrative review was made of the current evidence about immunity against coronavirus and its applicability to SARS-CoV-2. The physiopathogenesis is also described, along with the underlying leucocyte activity, with the intention of clarifying the possible usefulness of inflammatory biomarkers and the development of personalised treatments."],"journal":"An Pediatr (Barc)","authors":["Garcia-Salido, Alberto"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32439309","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.anpedi.2020.04.016","keywords":["covid-19","coronavirus","immunity","inmunidad","sars-cov-2"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667535119521415168,"score":108.447266},{"pmid":32505070,"title":"Nebulized Lidocaine in COVID-19, An Hypothesis.","text":["Nebulized Lidocaine in COVID-19, An Hypothesis.","Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients' lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted.","Med Hypotheses","Ali, Ziad A","El-Mallakh, Rif S","32505070"],"abstract":["Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients' lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted."],"journal":"Med Hypotheses","authors":["Ali, Ziad A","El-Mallakh, Rif S"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32505070","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.mehy.2020.109947","keywords":["anti-inflammatories","covid-19","cytokine-storm","lidocaine","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668892488239153153,"score":105.962105},{"pmid":32425304,"pmcid":"PMC7227545","title":"Reflection on lower rates of COVID-19 in children: does childhood immunizations offer unexpected protection?","text":["Reflection on lower rates of COVID-19 in children: does childhood immunizations offer unexpected protection?","The incidence of COVID-19 in children and teenagers is only about 2% in China. Children had mild symptoms and hardly infected other children or adults. It is worth considering that children are the most vulnerable to respiratory pathogens, but fatal SARS-like virus had not caused severe cases among them. According to the pathological studies of COVID-19 and SARS, a sharp decrease in T lymphocytes leads to the breakdown of the immune system. The cellular immune system of children differs from that of adults may be the keystone of atypical clinical manifestations or even covert infection. The frequent childhood vaccinations and repeated pathogens infections might be resulting in trained immunity of innate immune cells, immune fitness of adaptive immune cells or cross-protection of antibodies in the children. Therefore, due to lack of specific vaccine, some vaccines for tuberculosis, influenza and pneumonia may have certain application potential for the front-line health workers in the prevention and control of COVID-19. However, for high-risk susceptible populations, such as the elderly with basic diseases such as hypertension and diabetes, it is necessary to explore the acclimatization effect of the planned immune process on their immunity to achieve the trained immunity or immune fitness, so as to improve their own antiviral ability.","Med Hypotheses","Lyu, Jinglu","Miao, Tianyu","Dong, Jiajia","Cao, Ranran","Li, Yan","Chen, Qianming","32425304"],"abstract":["The incidence of COVID-19 in children and teenagers is only about 2% in China. Children had mild symptoms and hardly infected other children or adults. It is worth considering that children are the most vulnerable to respiratory pathogens, but fatal SARS-like virus had not caused severe cases among them. According to the pathological studies of COVID-19 and SARS, a sharp decrease in T lymphocytes leads to the breakdown of the immune system. The cellular immune system of children differs from that of adults may be the keystone of atypical clinical manifestations or even covert infection. The frequent childhood vaccinations and repeated pathogens infections might be resulting in trained immunity of innate immune cells, immune fitness of adaptive immune cells or cross-protection of antibodies in the children. Therefore, due to lack of specific vaccine, some vaccines for tuberculosis, influenza and pneumonia may have certain application potential for the front-line health workers in the prevention and control of COVID-19. However, for high-risk susceptible populations, such as the elderly with basic diseases such as hypertension and diabetes, it is necessary to explore the acclimatization effect of the planned immune process on their immunity to achieve the trained immunity or immune fitness, so as to improve their own antiviral ability."],"journal":"Med Hypotheses","authors":["Lyu, Jinglu","Miao, Tianyu","Dong, Jiajia","Cao, Ranran","Li, Yan","Chen, Qianming"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425304","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.mehy.2020.109842","keywords":["covid-19","childhood immunization","immune fitness","mild symptom in children","trained immunity"],"locations":["China","pneumonia"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667252837856313344,"score":104.811165},{"pmid":32470785,"title":"Reflection on lower rates of COVID-19 in children: Does childhood immunizations offer unexpected protection?","text":["Reflection on lower rates of COVID-19 in children: Does childhood immunizations offer unexpected protection?","The incidence of COVID-19 in children and teenagers is only about 2% in China. Children had mild symptoms and hardly infected other children or adults. It is worth considering that children are the most vulnerable to respiratory pathogens, but fatal SARS-like virus had not caused severe cases among them. According to the pathological studies of COVID-19 and SARS, a sharp decrease in T lymphocytes leads to the breakdown of the immune system. The cellular immune system of children differs from that of adults may be the keystone of atypical clinical manifestations or even covert infection. The frequent childhood vaccinations and repeated pathogens infections might be resulting in trained immunity of innate immune cells, immune fitness of adaptive immune cells or cross-protection of antibodies in the children. Therefore, due to lack of specific vaccine, some vaccines for tuberculosis, influenza and pneumonia may have certain application potential for the front-line health workers in the prevention and control of COVID-19. However, for high-risk susceptible populations, such as the elderly with basic diseases such as hypertension and diabetes, it is necessary to explore the remedial effect of the planned immune process on their immunity to achieve the trained immunity or immune fitness, so as to improve their own antiviral ability.","Med Hypotheses","Lyu, Jinglu","Miao, Tianyu","Dong, Jiajia","Cao, Ranran","Li, Yan","Chen, Qianming","32470785"],"abstract":["The incidence of COVID-19 in children and teenagers is only about 2% in China. Children had mild symptoms and hardly infected other children or adults. It is worth considering that children are the most vulnerable to respiratory pathogens, but fatal SARS-like virus had not caused severe cases among them. According to the pathological studies of COVID-19 and SARS, a sharp decrease in T lymphocytes leads to the breakdown of the immune system. The cellular immune system of children differs from that of adults may be the keystone of atypical clinical manifestations or even covert infection. The frequent childhood vaccinations and repeated pathogens infections might be resulting in trained immunity of innate immune cells, immune fitness of adaptive immune cells or cross-protection of antibodies in the children. Therefore, due to lack of specific vaccine, some vaccines for tuberculosis, influenza and pneumonia may have certain application potential for the front-line health workers in the prevention and control of COVID-19. However, for high-risk susceptible populations, such as the elderly with basic diseases such as hypertension and diabetes, it is necessary to explore the remedial effect of the planned immune process on their immunity to achieve the trained immunity or immune fitness, so as to improve their own antiviral ability."],"journal":"Med Hypotheses","authors":["Lyu, Jinglu","Miao, Tianyu","Dong, Jiajia","Cao, Ranran","Li, Yan","Chen, Qianming"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470785","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.mehy.2020.109842","keywords":["covid-19","childhood immunization","immune fitness","mild symptom in children","trained immunity"],"locations":["China","pneumonia"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668167109999329280,"score":104.811165},{"pmid":32505066,"title":"COVID-19: Loss of bridging between innate and adaptive immunity?","text":["COVID-19: Loss of bridging between innate and adaptive immunity?","COVID-19 has spread to most countries in the world. However, there are some striking differences in how COVID-19 is behaving in different age groups. While data on COVID-19 is limited, children appear to be less susceptible to severe disease. These unique characteristics may be considered as a potential link to understanding the immune system and response in COVID-19 and lead to an effective cure to the disease. We suggest a possible role of loss of bridging between innate and adaptive immunity in COVID-19 and a potential treatment modality also discussed.","Med Hypotheses","Rao, Vishal U S","Arakeri, Gururaj","Subash, Anand","Rao, Jyothsna","Jadhav, Sachin","Suhail Sayeed, Mufti","Rao, Gururaj","Brennan, Peter A","32505066"],"abstract":["COVID-19 has spread to most countries in the world. However, there are some striking differences in how COVID-19 is behaving in different age groups. While data on COVID-19 is limited, children appear to be less susceptible to severe disease. These unique characteristics may be considered as a potential link to understanding the immune system and response in COVID-19 and lead to an effective cure to the disease. We suggest a possible role of loss of bridging between innate and adaptive immunity in COVID-19 and a potential treatment modality also discussed."],"journal":"Med Hypotheses","authors":["Rao, Vishal U S","Arakeri, Gururaj","Subash, Anand","Rao, Jyothsna","Jadhav, Sachin","Suhail Sayeed, Mufti","Rao, Gururaj","Brennan, Peter A"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32505066","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.mehy.2020.109861","keywords":["adaptive immunity","covid-19","cytokines","innate immunity","interferons (ifns)","sars-cov2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668892488263270402,"score":101.67641}]}